180 related articles for article (PubMed ID: 22867528)
1. Synthesis, screening and computational investigation of pentacycloundecane-peptoids as potent CSA-HIV PR inhibitors.
Makatini MM; Petzold K; Arvidsson PI; Honarparvar B; Govender T; Maguire GE; Parboosing R; Sayed Y; Soliman ME; Kruger HG
Eur J Med Chem; 2012 Nov; 57():459-67. PubMed ID: 22867528
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors.
Makatini MM; Petzold K; Alves CN; Arvidsson PI; Honarparvar B; Govender P; Govender T; Kruger HG; Sayed Y; JerônimoLameira ; Maguire GE; Soliman ME
J Enzyme Inhib Med Chem; 2013 Feb; 28(1):78-88. PubMed ID: 22339087
[TBL] [Abstract][Full Text] [Related]
3. Pentacycloundecane-diol-based HIV-1 protease inhibitors: biological screening, 2D NMR, and molecular simulation studies.
Honarparvar B; Makatini MM; Pawar SA; Petzold K; Soliman ME; Arvidsson PI; Sayed Y; Govender T; Maguire GE; Kruger HG
ChemMedChem; 2012 Jun; 7(6):1009-19. PubMed ID: 22544389
[TBL] [Abstract][Full Text] [Related]
4. Pentacycloundecane derived hydroxy acid peptides: a new class of irreversible non-scissile ether bridged type isoster as potential HIV-1 wild type C-SA protease inhibitors.
Karpoormath R; Sayed Y; Govender P; Govender T; Kruger HG; Soliman MES; Maguire GEM
Bioorg Chem; 2012 Feb; 40(1):19-29. PubMed ID: 21982718
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structural studies of pentacycloundecane-based HIV-1 PR inhibitors: a hybrid 2D NMR and docking/QM/MM/MD approach.
Makatini MM; Petzold K; Sriharsha SN; Ndlovu N; Soliman ME; Honarparvar B; Parboosing R; Naidoo A; Arvidsson PI; Sayed Y; Govender P; Maguire GE; Kruger HG; Govender T
Eur J Med Chem; 2011 Sep; 46(9):3976-85. PubMed ID: 21741133
[TBL] [Abstract][Full Text] [Related]
6. Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.
Makatini MM; Petzold K; Sriharsha SN; Soliman ME; Honarparvar B; Arvidsson PI; Sayed Y; Govender P; Maguire GE; Kruger HG; Govender T
Bioorg Med Chem Lett; 2011 Apr; 21(8):2274-7. PubMed ID: 21429747
[TBL] [Abstract][Full Text] [Related]
7. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
8. Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations.
Wittayanarakul K; Aruksakunwong O; Sompornpisut P; Sanghiran-Lee V; Parasuk V; Pinitglang S; Hannongbua S
J Chem Inf Model; 2005; 45(2):300-8. PubMed ID: 15807491
[TBL] [Abstract][Full Text] [Related]
9. Structural and dynamical properties of different protonated states of mutant HIV-1 protease complexed with the saquinavir inhibitor studied by molecular dynamics simulations.
Aruksakunwong O; Wittayanarakul K; Sompornpisut P; Sanghiran V; Parasuk V; Hannongbua S
J Mol Graph Model; 2006 Nov; 25(3):324-32. PubMed ID: 16504560
[TBL] [Abstract][Full Text] [Related]
10. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
[TBL] [Abstract][Full Text] [Related]
12. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
Li D; Liu MS; Ji B; Hwang KC; Huang Y
Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379
[TBL] [Abstract][Full Text] [Related]
13. Active site binding modes of curcumin in HIV-1 protease and integrase.
Vajragupta O; Boonchoong P; Morris GM; Olson AJ
Bioorg Med Chem Lett; 2005 Jul; 15(14):3364-8. PubMed ID: 15950462
[TBL] [Abstract][Full Text] [Related]
14. Linear and cyclic glycopeptide as HIV protease inhibitors.
Pawar SA; Jabgunde AM; Maguire GE; Kruger HG; Sayed Y; Soliman ME; Dhavale DD; Govender T
Eur J Med Chem; 2013 Feb; 60():144-54. PubMed ID: 23291117
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and NMR assignment of pentacycloundecane precursors of potential pharmaceutical agents.
Onajole OK; Makatini MM; Govender P; Govender T; Maguire GE; Kruger HG
Magn Reson Chem; 2010 Mar; 48(3):249-55. PubMed ID: 20084637
[TBL] [Abstract][Full Text] [Related]
16. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
[TBL] [Abstract][Full Text] [Related]
17. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
Qiu X; Zhao GD; Tang LQ; Liu ZP
Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations.
Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S
J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
